Current Edition


Dedicated research specialist MeDiNova has appointed Annabel Elliott Senior Director of Quality as part of its plans for continued global expansion.
Annabel brings a wealth of clinical research experience at senior level, with extensive knowledge of Quality systems, audits and regulatory requirements, including hosting regulatory authority inspections.
She will play an integral role in both MeDiNova’s ongoing expansion, which continues at a rapid pace globally, and further building its reputation as the most highly regarded site management organisation, also on a global basis, in terms of Quality.
Annabel is responsible for cultivating a Quality culture throughout the organisation and will implement systems and procedures to demonstrate MeDiNova’s commitment to achieving and maintaining the highest Quality standards
To complement Annabel’s appointment, every member of staff will be subject to ongoing training and support and the entire team will work to meet a series of KPIs which will be regularly monitored.
Annabel said: “MeDiNova is highly respected in the clinical research industry. It has built an excellent reputation as a Global SMO over the years and is fast becoming established across the world. I am delighted to be a part of MeDiNova’s journey going forward.”
Kumar Muthalagappan OBE BSC (Hons) FCA, Chief Executive of MeDiNova, welcomed Annabel to the team.
He said: “Annabel is very determined and enthusiastic in taking on the challenge to make Quality one of the key business differentiators for MeDiNova when compared with the other Global SMOs.
“We wish her well in her efforts and offer her our full support.”
MeDiNova is positioned to be the leading global site management organisation in terms of Quality, Recruitment and Delivery.  With significant global reach, the company now operates 36 sites in four countries – the UK, United States, South Africa and Spain.  In the past 18 months MeDiNova has also doubled its sites in the UK, opening three new Dedicated Research Centres in Yorkshire; Northamptonshire and Warwickshire.
It conducts studies for major pharmaceutical companies on potential treatments for a wide variety of conditions and diseases, including Asthma, Osteoarthritis, Chronic Obstructive Pulmonary Disease (COPD), Diabetes and vaccine studies.